## TMO: Thermo Fisher Scientific Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.2% below STRENGTH zone (4.0-10.0%); PEG 1.95 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($542.77)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Epoch Investment Partners Inc. Sells 53,867 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251206T095055 | Somewhat-Bullish | Relevance: 100%
- Epoch Investment Partners Inc. reduced its stake in Thermo Fisher Scientific Inc. by 39.8% in the second quarter, selling 53,867 shares and holding 81,408 shares valued at $33.008 million. Other institutional investors have also adjusted holdings, while company insiders have sold a total of 149,271 shares worth over $86 million in the last ninety days. Thermo Fisher Scientific recently announced a $5.00 billion stock repurchase program and a quarterly dividend of $0.43 per share.

**2. Stenger Family Office LLC Makes New $1.01 Million Investment in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251206T130851 | Bullish | Relevance: 99%
-  Stenger Family Office LLC has made a new investment of $1.01 million in Thermo Fisher Scientific Inc. by purchasing 2,491 shares. This comes as Thermo Fisher topped its Q3 results, authorized a $5.0 billion share buyback, and continues to hold an average analyst rating of "Moderate Buy." Insider selling has been noted, while institutional investors collectively own a significant portion of the company's stock.

**3. Cerity Partners LLC Sells 2,142 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251208T090850 | Somewhat-Bullish | Relevance: 98%
- Cerity Partners LLC reduced its stake in Thermo Fisher Scientific Inc. by 0.9%, selling 2,142 shares and retaining 224,635 shares valued at approximately $91.08 million. This comes amidst significant insider selling, with COO Michel Lagarde selling 32,000 shares and other insiders selling a total of 149,271 shares in the last three months. Thermo Fisher Scientific has also announced a $5.0 billion stock repurchase program, declared a quarterly dividend of $0.43, and reported strong Q3 earnings exceeding estimates, along with positive FY2025 guidance.

**4. Cresset Asset Management LLC Purchases 7,364 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251206T094155 | Somewhat-Bullish | Relevance: 98%
-  Cresset Asset Management LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 25.2%, acquiring an additional 7,364 shares to hold a total of 36,591 shares valued at approximately $14.85 million. This comes as Thermo Fisher Scientific reported strong quarterly earnings, implemented a $5 billion share buyback program, and declared a $0.43 quarterly dividend. However, significant insider selling has also been noted, with the CEO and an EVP selling a substantial number of shares recently.

**5. Natixis Has $23.43 Million Stock Position in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251209T132304 | Bullish | Relevance: 98%
- Natixis significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 127.6% in the second quarter, bringing its holding to 57,783 shares valued at $23.43 million. Other institutional investors also adjusted their positions in the medical research company, which recently reported strong earnings and announced a quarterly dividend of $0.43 per share. Wall Street analysts maintain a "Moderate Buy" rating for TMO, with a consensus price target of $612.95.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Keybanc | $750 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $670 | $656 | +2% |
| 2025-12-01 | HSBC | $670 | $550 | +22% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Keybanc | up | Overweight |
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-12-01 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($1.76M) |
| Sells | 14 ($41.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.6% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $42M sold (14 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.95 elevated, pricing in significant growth expectations. Forward P/E 23.1x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (2 raises, avg +12%). Insider selling cluster ($41.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $213.5B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.95 |
| Forward P/E | 23.1 |
| Current P/E | 25.0 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.6% to -4.2% (-2.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.2pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.18x) but short-term weakness (below SMA20). MACD histogram bearish (-3.65), momentum weakening. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.17% (CS: 21) | Weak |
| RSI_14 | 46.5 | Neutral |
| MACD Histogram | -3.65 | Bearish |
| vs SMA20 | 0.978x | Below |
| vs SMA50 | 1.017x | Above |
| vs SMA200 | 1.181x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $568.21
- **Stop Loss:** $542.77 (4.5% risk)
- **Target:** $593.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 19
- **Position Value:** $10,795.99
- **Portfolio %:** 10.80%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*